Navigation Links
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Date:8/11/2009

THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation therapy (ADT) leading to bone loss. In both studies, published today in The New England Journal of Medicine (NEJM), patients receiving twice-yearly denosumab experienced significant increases in bone mineral density (BMD) compared to placebo, associated with more than 60 percent reduction in vertebral fracture in both patient populations.(1,2) These data were previously reported by Amgen at medical congresses.

To view the Multimedia News Release, go to:http://www.prnewswire.com/mnr/amgen/39203/

"The discovery of the RANK Ligand pathway represents a significant advance in the understanding of bone biology," said Roland Baron, Ph.D., D.D.S., professor and chair of department of Oral Medicine, Infection, and Immunity at the Harvard School of Dental Medicine. "These results demonstrate that targeting the RANK Ligand pathway with denosumab could represent a promising new approach in two different disease settings characterized by bone loss."

FREEDOM Osteoporosis Study Results: Significant Fracture Reduction Seen Across the Skeleton in Postmenopausal Women with Osteoporosis

Results from the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every six Months) study, showed that women receiving a subcutaneous shot of d
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... MONTVALE, N.J. , May 17, 2013 /PRNewswire/ ... imaging, and Hitachi-Aloka Medical, a global leader in ... the two global companies to enable further innovation ... For years, the Hitachi-Aloka ultrasound systems and PENTAX ... world,s most trusted families of EUS systems. This ...
(Date:5/17/2013)... 2013 Sinovac Biotech Ltd. (Nasdaq: SVA ... , today announced that it will release its unaudited ... before market on Tuesday, May 28, 2013.  The Company will ... 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China ... an update on recent corporate developments. To access ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
...  InfuSystem Holdings, Inc. (NYSE Amex: INFU ) ... related services, today announced that the previously announced request ... Capital and certain affiliates (the "Kleinheinz Dissident Group") to ... valid based upon a report by an independent inspector ...
...  Berg Biosystems and Berg Diagnostics, members of the Berg Pharma ... Spectrum Disorder (ASD) Biomarker Discovery Using the Berg Interrogative ... meeting in San Francisco, CA. The study was conducted by ... cases where more than 1 child was afflicted by the ...
Cached Medicine Technology:InfuSystem Provides Update on Special Meeting of Stockholders 2Berg Pharma Companies Present Groundbreaking Approach to Understanding Autism and Identify Novel Biomarkers That May be Crucial in Diagnosis 2Berg Pharma Companies Present Groundbreaking Approach to Understanding Autism and Identify Novel Biomarkers That May be Crucial in Diagnosis 3
(Date:5/20/2013)... 2013 Gerald Wojtala, executive director of ... at North Carolina Food Safety and Defense Task Force’s ... Need for Partnerships – from Farm to Fork – ... for May 22-23 at the Sheraton Imperial Hotel, will ... sector have in protecting the food supply. , Wojtala ...
(Date:5/19/2013)... The special introductory offer for the ... soon. "We are so excited to introduce our serum ... Beauty®. "It is a pleasure to use, it is ... also moisturizes the skin. One of the powerful ingredients ... is very successful in clinical studies." , Collagen makes ...
(Date:5/19/2013)... the heterogeneity the variety of genetic mutations of ... patients with the most common type of head and neck ... Cancer , investigators at Massachusetts General Hospital (MGH) and ... a better predictor of survival than most traditional risk factors ... of the head and neck. , "Our findings ...
(Date:5/19/2013)... Alonso Krangle LLP a dedicated law firm , ... on behalf of a-24-year-old financial analyst rendered quadriplegic as a ... accident lawsuit, which was filed in the Supreme Court for ... the property out as a bathing beach, but posted absolutely ... No. 34556/12) , According to the diving accident lawsuit complaint, ...
(Date:5/19/2013)... The three surgeons from the Center for ... Abrutyn, M.D., Robert S. Boretz, M.D., and Thomas J. ... current location, 215 Union Avenue, Suite B, Bridgewater, N.J. ... medicine, with emphasis on injuries of the knee and ... for a wide range of orthopedic problems. Dr. Abrutyn's ...
Breaking Medicine News(10 mins):Health News:IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference 2Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 2Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 3Health News:Alonso Krangle Files Diving Accident Lawsuit on Behalf of Suffolk County Man Rendered Quadraplegic in Tragic Diving Accident at Long Island Beach 2Health News:Alonso Krangle Files Diving Accident Lawsuit on Behalf of Suffolk County Man Rendered Quadraplegic in Tragic Diving Accident at Long Island Beach 3Health News:Summit Medical Group Welcomes the Center for Orthopedic Care 2Health News:Summit Medical Group Welcomes the Center for Orthopedic Care 3
... business with the independence and sustainability to deliver significant improvements ... on HIV with industry-leading pipeline to deliver more new HIV ... Pfizer , LONDON and PHILADELPHIA, April 16 GlaxoSmithKline plc ... PFE ) today announced they have entered into an ...
... April 16, 2009) NEW YORK, April 16 A rich ... in the New York area received a comprehensive voice check-up ... at the second annual free Voice Screening for Professional Singers, ... Infirmary and MusiCares, the charitable arm of the ...
... MONTREAL, April 16 Messaging Architects ( ... email security and compliance, will present its latest ... RSA Conference (April 19-24), the world,s premier information ... consistently attracts the industry,s leading providers of email ...
... month , ... Raleigh and Rocky Mount, N.C. (PRWEB) April 16, 2009 ... is pleased to announce the launch of the 2009 HensonFuerst Health Initiative, ... service efforts. The initiative was developed as a way to encourage both ...
... /PRNewswire-Asia-FirstCall/ -- SOKO Fitness & Spa,Group, Inc. (OTC Bulletin ... in Northern China, announced its operating results for the ... Total revenue for the quarter was $5.1 ... the previous year. For the nine months ended February ...
... saving lives, the MedicAlert Foundation partners with Thrive ... medical information in an emergencyTURLOCK, Calif., April 15 ... in providing emergency response medical information services, today ... Allergy & Gluten-free Expo in 2009, taking place ...
Cached Medicine News:Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 2Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 3Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 4Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 5Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 6Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 7Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 8Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 9Health News:Singers Hit High Notes in Free Voice Screening at The New York Eye and Ear Infirmary 2Health News:Comprehensive Email Lifecycle Management Focus for Messaging Architects at RSA Conference 2Health News:HensonFuerst Announces Year-Round Community Program 2Health News:HensonFuerst Announces Year-Round Community Program 3Health News:SOKO Fitness & Spa Group Announces Third Quarter FY2009 Financial Results 2Health News:SOKO Fitness & Spa Group Announces Third Quarter FY2009 Financial Results 3Health News:MedicAlert Brings History of Saving Lives to Chicago for Inaugural Thrive Allergy & Gluten-free Expo 2
... The Vitros 250 is a ... requirements in multiple environments ... hospitals, clinics and satellite locations. ... on-board dilution, and can be ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
Medicine Products: